Ballew Advisors’s Synergy Pharmaceuticals, Inc Common Stock SGYP Stock Holding History

Ballew Advisors’s Portfolio SGYP Stock Details SGYP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-26,200	Closed	-$8K	–	94
2018 Q4	$8K	Hold	26,200	–	–	0.01%	91
2018 Q3	$11K	Hold	26,200	–	–	0.01%	285
2018 Q2	$46K	Hold	26,200	–	–	0.05%	163
2018 Q1	$48K	Sell	26,200 -100	-0.4%	-$211	0.04%	166
2017 Q4	$59K	Buy	+26,300	New	+$65.4K	0.06%	100

Other funds holding SGYP

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Ballew Advisors's SGYP Position: Q1 2019 in Review

Ballew Advisors sold out of Synergy Pharmaceuticals, Inc Common Stock (SGYP) in Q1 2019, closing a stake of 26,200 shares — an estimated $8K sold.

Ballew Advisors first reported a position in SGYP in Q4 2017 and held it in 5 quarters. The position peaked at $59K in Q4 2017. 12 funds tracked by Wall St. Rank hold SGYP as of Q1 2019.

Ballew Advisors reported no remaining Synergy Pharmaceuticals, Inc Common Stock position as of Q1 2019 after selling out during the quarter.
Ballew Advisors sold 26,200 Synergy Pharmaceuticals, Inc Common Stock shares in Q1 2019, an estimated $8K.
Ballew Advisors first reported a position in Synergy Pharmaceuticals, Inc Common Stock in Q4 2017 and held it in 5 quarters.
Ballew Advisors's Synergy Pharmaceuticals, Inc Common Stock position peaked at $59K in Q4 2017.
12 funds tracked by Wall St. Rank held Synergy Pharmaceuticals, Inc Common Stock as of Q1 2019.

Based on Ballew Advisors's 13F filing for Q1 2019, filed 8 May 2019.